ReviewPediatric gastroenterology, hepatology & nutrition2026
Maintenance Enteral Nutrition in Paediatric Crohn's Disease: A Systematic Review and Meta-Analysis.
Review in Pediatric gastroenterology, hepatology & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Maintenance enteral nutrition (MEN) is a dietary strategy that can be used to sustain remission in children with Crohn's disease (CD) following induction therapy with exclusive enteral nutrition (EEN) or corticosteroids. Unlike EEN, MEN involves partial nutritional intake (typically 25-60% of energy needs) via polymeric or elemental formula given alongside regular food. This systematic review aimed to evaluate the clinical effectiveness of MEN for maintaining remission and supporting growth. To determine whether MEN is effective in maintaining remission in children with CD and to assess its impact on inflammatory markers and anthropometric outcomes. Methods: Five databases (Medline, Embase, CINAHL, Scopus, Web of Science) were searched up to April 30 2025. Eligible studies included children (≤18 years) with CD who initiated MEN following defined induction with EEN or corticosteroids and reported outcomes related to relapse, remission, or growth. Risk of bias was assessed using ROBINS-I and RoB 2 tools. Random-effects meta-analyses were used for synthesis. Although this review was not prospectively registered, a predefined protocol was developed and followed. Results: Five studies were included, enrolling a total of 271 participants with usable relapse data. MEN was associated with significantly lower relapse risk compared to controls (pooled odds ratio, 0.455; 95% confidence interval, 0.216-0.957; Conclusion: MEN is associated with reduced risk of relapse and improved nutritional status in children with CD. Standardized protocols and high-quality trials are needed to confirm optimal use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.